Clinical case of stent thrombosis four months after percutaneous coronary intervention
https://doi.org/10.33667/2078-5631-2020-21-86-88
Abstract
The article examines the reasons for restenosis of the Calypso stent with a bioresorbent coating three months after installation by 90–95% on the background of self-withdrawal of atorvastatin and ticagrelor. Recommendations for myocardial revascularization of the European Society of Cardiology and the European Association of Cardiothoracic Surgeons, dual antiplatelet therapy are presented. The problems of stent restenosis associated with various methods of percutaneous coronary intervention are discussed. The data of the Russian register RECORD‑3 on adherence to treatment with statins and antiplatelet agents after percutaneous coronary intervention are presented.
About the Authors
N. V. Orlova
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
M. A. Laperishvili
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
T. A. Sabirov
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Moscow
Russian Federation
Moscow
G. A. Chuvaryan
City Clinical Hospital No. 13
Russian Federation
Moscow
Russian Federation
Moscow
A. R. Poga
City Clinical Hospital No. 13
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Farb A, Sangiorgi G, Carter AJ. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99: 44–52.
2. Douketis J.D., Spyropoulos A. C., Spencer F.A. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 suppl): 326–50.
3. Hodgson J.M., Stone G.W., Michael L.A., et al. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent task force. Catheter. Cardiovasc. Interv. 2007; 69: 327–333.
4. Fu H, Alabdullah M, Großmann J, et al. The differential statin effect on cytokine production of monocytes or macrophages is mediated by differential geranylgeranylation-dependent Rac1 activation. Cell Death Dis. 2019; 10 (12): 880.
5. Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson et al. Рекомендации ESC/EACTS по реваскуляризации миокарда 2018; 76 с.
6. Milà L, Barrabés JA, Lidón RM, et al. Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome. Rev Esp Cardiol (Engl Ed). 2019; 19: 30293–2.
7. Эрлих А.Д. Шестимесячные исходы у пациентов с острым коронарным синдромом, включенных в российский регистр РЕКОРД 3. Российский кардиологический журнал 2017, 11 (151): 8–14.
8. Sulimov V.A., Moroz E.V. Antiplatelet drug resistance in patients with coronary heart disease. Cardiovascular Therapy and Prevention. 2012; 11 (6): 71–77.
Review
For citations:
Orlova N.V., Laperishvili M.A., Sabirov T.A., Chuvaryan G.A., Poga A.R. Clinical case of stent thrombosis four months after percutaneous coronary intervention. Medical alphabet. 2020;(21):86-88. (In Russ.) https://doi.org/10.33667/2078-5631-2020-21-86-88
Views:
393
Email this article 